Javascript must be enabled to continue!
Role of PAF in the late airway microvascular leakage induced by antigen in IgE‐sensitized rat
View through CrossRef
Summary—The effect of the antagonist of platelet‐activating factor (PAF), BN 50730, on PAF‐and antigen‐ induced increase in microvascular leakage, using Evans blue dye as an index of permeability, was investigated in rat pulmonary tissues. PAF (1 μg/kg, iv) induced a marked increase in Evans blue dye content in trachea, main bronchi and small bronchi, that was significantly reduced upon pretreatment of the rats with BN 50730 (25 mg/kg, orally) and by the serotonin antagonist, methysergide (1 mg/kg, iv), only in the small bronchi. Serotonin also induced an increase in microvascular leakage in the three tissues that was significantly inhibited when the animals were treated with methysergide but not by BN 50730. In contrast, histamine and lyso‐PAF did not induce significant increase in Evans blue dye content. Intravenous injection of antigen to IgE‐sensitized rats induced a biphasic increase in vascular permeability. An early increase in vascular permeability in trachea, main bronchi and small bronchi was observed 10 minutes after the injection of the antigen, and this phenomenon was significantly reduced upon treatment of the rats with methysergide, whereas, BN 50730 was ineffective. A late increase in vascular permeability was noted in the three tissues, with a maximum at 120 minutes and representing 30–40% of the magnitude of the first phase. Administration of BN 50730 (25 mg/kg) to the animals, evoked a significant inhibition of this increase in microvascular leakage, whereas, methysergide only significantly reduced the one induced by antigen in the trachea. These results demonstrate that the early (10 min) antigen‐induced microvascular leakage of the trachea, main bronchi and small bronchi in IgE‐sensitized rats is primarily due to the release of serotonin. However, the late increase (120 min) in vascular permeability involves PAF generation, as demonstrated by the marked inhibition of this process by the selective PAF antagonist BN 50730.
Title: Role of PAF in the late airway microvascular leakage induced by antigen in IgE‐sensitized rat
Description:
Summary—The effect of the antagonist of platelet‐activating factor (PAF), BN 50730, on PAF‐and antigen‐ induced increase in microvascular leakage, using Evans blue dye as an index of permeability, was investigated in rat pulmonary tissues.
PAF (1 μg/kg, iv) induced a marked increase in Evans blue dye content in trachea, main bronchi and small bronchi, that was significantly reduced upon pretreatment of the rats with BN 50730 (25 mg/kg, orally) and by the serotonin antagonist, methysergide (1 mg/kg, iv), only in the small bronchi.
Serotonin also induced an increase in microvascular leakage in the three tissues that was significantly inhibited when the animals were treated with methysergide but not by BN 50730.
In contrast, histamine and lyso‐PAF did not induce significant increase in Evans blue dye content.
Intravenous injection of antigen to IgE‐sensitized rats induced a biphasic increase in vascular permeability.
An early increase in vascular permeability in trachea, main bronchi and small bronchi was observed 10 minutes after the injection of the antigen, and this phenomenon was significantly reduced upon treatment of the rats with methysergide, whereas, BN 50730 was ineffective.
A late increase in vascular permeability was noted in the three tissues, with a maximum at 120 minutes and representing 30–40% of the magnitude of the first phase.
Administration of BN 50730 (25 mg/kg) to the animals, evoked a significant inhibition of this increase in microvascular leakage, whereas, methysergide only significantly reduced the one induced by antigen in the trachea.
These results demonstrate that the early (10 min) antigen‐induced microvascular leakage of the trachea, main bronchi and small bronchi in IgE‐sensitized rats is primarily due to the release of serotonin.
However, the late increase (120 min) in vascular permeability involves PAF generation, as demonstrated by the marked inhibition of this process by the selective PAF antagonist BN 50730.
Related Results
Analysis methods on clinical data drawn from persistent atrial fibrillation
Analysis methods on clinical data drawn from persistent atrial fibrillation
Background
The persistent atrial fibrillation (PAF) is one of the most common arrhythmia. Its incidence is increasing recently. PAF is an important issue in our s...
IgE glycans promote IgG anti-IgE autoantibodies that facilitate IgE serum clearance via CD23
IgE glycans promote IgG anti-IgE autoantibodies that facilitate IgE serum clearance via CD23
Background
: IgE antibodies are involved in type-1
hypersensitivity. Cross-linking IgE bound to the high-affinity IgE
receptor, FceRI on effector cells with an al...
Genesis of host IgE competence: perinatal IgE tolerance induced by IgE processed and presented by IgE Fc receptor (CD23)‐bearing B cells
Genesis of host IgE competence: perinatal IgE tolerance induced by IgE processed and presented by IgE Fc receptor (CD23)‐bearing B cells
AbstractA murine model for studying life‐long IgE tolerance was previously developed in this laboratory by perinatal IgE injection into neonates. Herein, we demonstrated that norma...
Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response.
Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response.
Abstract
The prolonged inhibition of IgE synthesis in mice caused by perinatal inoculation of IgE is attributable, at least in part, to the formation of anti-IgE ...
TGF Presence During IgE-dependent Sensitization Primes Mast Cells for Higher VEGF Production After Fc RI Activation
TGF Presence During IgE-dependent Sensitization Primes Mast Cells for Higher VEGF Production After Fc RI Activation
Binding of monomeric Immunoglobulin E (IgE) to the high affinity IgE receptor (FcεRI) on mast cells induces a sensitization process which increases cell survival, augments membrane...
In vitro binding of an IgE protein to human platelets.
In vitro binding of an IgE protein to human platelets.
Abstract
Bronchoconstriction in extrinsic asthma is initiated by mediators released from IgE-sensitized leukocytes after contact with polyvalent antigen. Because pla...
Study on the Role of Platelet-Activating Factor in Promoting Relapse of Multiple Myeloma after CAR-T Therapy
Study on the Role of Platelet-Activating Factor in Promoting Relapse of Multiple Myeloma after CAR-T Therapy
Aims: Multiple myeloma (MM) is a malignant plasma cell disease. While CAR-T therapy is highly effective in the early stages of MM treatment, most patients still face relapse. Plate...
Anti-IgE monoclonal antibodies that bind to IgE bound by CD23 but not to IgE bound by IgE Fc receptors on basophils (86.10)
Anti-IgE monoclonal antibodies that bind to IgE bound by CD23 but not to IgE bound by IgE Fc receptors on basophils (86.10)
Abstract
IgE is a central mediator responsible for immediate-type hypersensitivity reactions. The anti-IgE monoclonal antibody (mAb), omalizumab, has been shown i...

